Purchase this article with an account.
Marisse Masis, Shan Lin, Paul Coh; Micropulse transscleral diode laser cyclophotocoagulation: mid to long-term results and anatomical effects. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4993.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the short-term results of Micropulse transscleral diode laser cyclophotocoagulation (MP-TCP) and its functional and anatomical safety profile.
MP-TCP (MP3, Iridex Corporation, Mountain View, CA) was performed in 40 patients. Exposure time was 80 seconds for each 180° hemisphere, for a total of 160 seconds and 360° with a power of 2000mW. Some eyes were double treated or retreated at a later time. UBM and AS-OCT were performed in selected patients before and 7 days after treatment. Intraocular pressure (IOP) was monitored.
Success was defined as IOP lowering ≥20% with medications and was achieved in 66% of the cases, with a mean follow-up of 258 days. Diagnoses included primary open angle glaucoma, pigmentary glaucoma, pseudoexfoliation glaucoma, glaucoma associated with steroid use, neovascular glaucoma and normal tension glaucoma. Suprachoroidal space, scleral spur, and angle dimensions were assessed by UBM in 8 patients. AS-OCT was performed in 12 patients to evaluate anterior chamber and angle structures, iris features, and the anterior capsule of the lens. No presence of suprachoroidal fluid or anatomical change was found, and objective parameters did not significantly change.
MP-TCP is effective at lowering IOP in the majority of patients, and appears safe without major complications.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only